Abbv 011 News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Abbv 011. Real-time updates on events, politics, business and more.

Dr Johnson on ABBV-011 in Small Cell Lung Cancer

July 21, 2023

Melissa L. Johnson, MD, discusses the development of the seizure-related homolog protein 6–targeting antibody-drug conjugate ABBV-011 and outcomes with this agent in patients with small cell lung cancer.

Melissal Johnson Tristar Centennial Medical Center Sarah Cannon Research Institute Lung Cancer Research Oncology Department Medical Executive Committee

Source: onclive.com

ABBV-011 Showcases Early Tolerability, Antitumor Activity in Small Cell Lung Cancer

June 5, 2023

The SEZ6-targeted antibody-drug conjugate ABBV-011, when administered at 1 mg/kg every 3 weeks, was found to be well tolerated and to demonstrate early efficacy in patients with relapsed or refractory small cell lung cancer.

Bristol Myers Squibb Bristol Myers Squibb Medarex Daniel Morgensztern Division Of Oncology Washington University School Of Medicine Veterans Administration Lung Study

Source: onclive.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Abbv 011 News Today

Dr Johnson on ABBV-011 in Small Cell Lung Cancer

ABBV-011 Showcases Early Tolerability, Antitumor Activity in Small Cell Lung Cancer

Explore More Categories